Cargando…

The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review

BACKGROUND: The role of robotic surgery (RS) for hilar cholangiocarcinoma (HC) is under investigation. Surgical resection is the only curative modality of treatment but extremely complex and high risk of morbidity and mortality may occur. The aim of this study is to perform a systematic review of pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Brolese, Alberto, Rigoni, Marta, Pasquale, Alessio, Viel, Giovanni, Brolese, Marco, Ciarleglio, Francesco Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552766/
https://www.ncbi.nlm.nih.gov/pubmed/36237328
http://dx.doi.org/10.3389/fonc.2022.1001838
_version_ 1784806320208084992
author Brolese, Alberto
Rigoni, Marta
Pasquale, Alessio
Viel, Giovanni
Brolese, Marco
Ciarleglio, Francesco Antonio
author_facet Brolese, Alberto
Rigoni, Marta
Pasquale, Alessio
Viel, Giovanni
Brolese, Marco
Ciarleglio, Francesco Antonio
author_sort Brolese, Alberto
collection PubMed
description BACKGROUND: The role of robotic surgery (RS) for hilar cholangiocarcinoma (HC) is under investigation. Surgical resection is the only curative modality of treatment but extremely complex and high risk of morbidity and mortality may occur. The aim of this study is to perform a systematic review of perioperative and oncological outcomes of RS for HC, across a comprehensive range of outcomes reported in recent literature. MATERIALS AND METHODS: PRISMA checklist was used as a basis for writing the systematic review and studies’ selection. Literature documenting RS for HC was analyzed by searching PubMed and Cochrane Library from 2009 to May 2022. The search terms, either independently or in combination, were used according to PICOT framework. The target population are patients treated with robotic surgical approach for HC. RESULTS: 12 studies with 109 patients were included after screening process. The Bismuth classification in all series except one was: 21 type I, 7 type II, 12 type IIIa, 26 type IIIb and 4 type IV. Mean operative time for a total of 21 patients was 644 minutes. Other two case series reported a median operative time of 375 with a console time of 276 minutes. Mean blood loss for case reports and two case series was 662 milliliters. Blood transfusion rate for all operation was 33.3%. Overall Conversion rate was 2.8%. Pooled post operative morbidity and mortality was 39.8% and 1.8% respectively. Mean LOS for case reports and one case series for a total of 17 patients was 16 days. R0 resection rate for the 11 papers was 74.3%. Seven out of 12 studies reported on the oncological follow up: median observation time ranged from 5 to 60 months, recurrence rate was 52.6% (range 0-90%) reported only in 19 patients (10/19). CONCLUSIONS: RS for HC was feasible and safe. However, although this systematic review could not be conclusive in most of the analyzed items, RS for the treatment of HC could represent the best tool for a future meticulous and precision surgery. The review’s results certainly indicate that further research in urgently is required on this field.
format Online
Article
Text
id pubmed-9552766
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95527662022-10-12 The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review Brolese, Alberto Rigoni, Marta Pasquale, Alessio Viel, Giovanni Brolese, Marco Ciarleglio, Francesco Antonio Front Oncol Oncology BACKGROUND: The role of robotic surgery (RS) for hilar cholangiocarcinoma (HC) is under investigation. Surgical resection is the only curative modality of treatment but extremely complex and high risk of morbidity and mortality may occur. The aim of this study is to perform a systematic review of perioperative and oncological outcomes of RS for HC, across a comprehensive range of outcomes reported in recent literature. MATERIALS AND METHODS: PRISMA checklist was used as a basis for writing the systematic review and studies’ selection. Literature documenting RS for HC was analyzed by searching PubMed and Cochrane Library from 2009 to May 2022. The search terms, either independently or in combination, were used according to PICOT framework. The target population are patients treated with robotic surgical approach for HC. RESULTS: 12 studies with 109 patients were included after screening process. The Bismuth classification in all series except one was: 21 type I, 7 type II, 12 type IIIa, 26 type IIIb and 4 type IV. Mean operative time for a total of 21 patients was 644 minutes. Other two case series reported a median operative time of 375 with a console time of 276 minutes. Mean blood loss for case reports and two case series was 662 milliliters. Blood transfusion rate for all operation was 33.3%. Overall Conversion rate was 2.8%. Pooled post operative morbidity and mortality was 39.8% and 1.8% respectively. Mean LOS for case reports and one case series for a total of 17 patients was 16 days. R0 resection rate for the 11 papers was 74.3%. Seven out of 12 studies reported on the oncological follow up: median observation time ranged from 5 to 60 months, recurrence rate was 52.6% (range 0-90%) reported only in 19 patients (10/19). CONCLUSIONS: RS for HC was feasible and safe. However, although this systematic review could not be conclusive in most of the analyzed items, RS for the treatment of HC could represent the best tool for a future meticulous and precision surgery. The review’s results certainly indicate that further research in urgently is required on this field. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9552766/ /pubmed/36237328 http://dx.doi.org/10.3389/fonc.2022.1001838 Text en Copyright © 2022 Brolese, Rigoni, Pasquale, Viel, Brolese and Ciarleglio https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Brolese, Alberto
Rigoni, Marta
Pasquale, Alessio
Viel, Giovanni
Brolese, Marco
Ciarleglio, Francesco Antonio
The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review
title The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review
title_full The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review
title_fullStr The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review
title_full_unstemmed The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review
title_short The role of robotic surgery for the treatment of hilar cholangiocarcinoma: A systematic review
title_sort role of robotic surgery for the treatment of hilar cholangiocarcinoma: a systematic review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552766/
https://www.ncbi.nlm.nih.gov/pubmed/36237328
http://dx.doi.org/10.3389/fonc.2022.1001838
work_keys_str_mv AT brolesealberto theroleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT rigonimarta theroleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT pasqualealessio theroleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT vielgiovanni theroleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT brolesemarco theroleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT ciarlegliofrancescoantonio theroleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT brolesealberto roleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT rigonimarta roleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT pasqualealessio roleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT vielgiovanni roleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT brolesemarco roleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview
AT ciarlegliofrancescoantonio roleofroboticsurgeryforthetreatmentofhilarcholangiocarcinomaasystematicreview